IGC · AMEX
IGC Pharma (IGC) Stock Price & Fundamentals
IGC Pharma (IGC) closed at $834.35 on Oct 9, 2026, down 1.44% from the previous close of $846.54.
Share price, past year
1Y +48.38%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $834.35 |
| Sep 30, 2026 | $841.12 |
| Aug 31, 2026 | $772.32 |
| Jul 31, 2026 | $795.19 |
| Jun 30, 2026 | $775.66 |
| May 29, 2026 | $725.37 |
| Apr 30, 2026 | $689.53 |
| Mar 31, 2026 | $682.10 |
| Feb 27, 2026 | $674.97 |
| Jan 30, 2026 | $638.67 |
| Dec 31, 2025 | $622.70 |
| Nov 28, 2025 | $592.56 |
| Oct 31, 2025 | $555.12 |
Key statistics
- Market cap
- $82.43B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 98.8M
- Dividend yield
- —
- 52-week range
- $547.99 – $856.14
IGC Pharma's market cap is $82.43B, based on a share price of $834.35 and 98.8M shares outstanding as of Mar 31, 2026.
Financials
IGC Pharma reported revenue of $1.27M for fiscal 2025, down 5.50% from fiscal 2024.
IGC Pharma reported a net loss of $7.12M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Mar 31, 2025 | $1.27M | −5.5% | −$7.12M | −560.4% | −$0.09 | −$4.91M |
| FY2024ended Mar 31, 2024 | $1.35M | +47.6% | −$13.00M | −966.5% | −$0.22 | −$5.34M |
| FY2023ended Mar 31, 2023 | $911.00K | +129.5% | −$11.51M | −1,263.0% | — | −$7.36M |
| FY2022ended Mar 31, 2022 | $397.00K | −55.8% | −$15.02M | −3,782.4% | — | −$7.70M |
| FY2021ended Mar 31, 2021 | $898.00K | −78.0% | −$8.81M | −981.2% | −$0.21 | −$12.27M |
| FY2020ended Mar 31, 2020 | $4.07M | −20.4% | −$7.32M | −179.6% | −$0.19 | −$13.07M |
| FY2019ended Mar 31, 2019 | $5.12M | +133.3% | −$4.10M | −80.1% | −$0.13 | −$3.35M |
| FY2018ended Mar 31, 2018 | $2.19M | +277.9% | −$1.79M | −81.4% | −$0.06 | −$2.07M |
| FY2017ended Mar 31, 2017 | $580.37K | −90.9% | −$1.87M | −321.7% | −$0.07 | −$1.54M |
| FY2016ended Mar 31, 2016 | $6.37M | — | −$2.81M | −44.1% | −$0.17 | −$279.89K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2026ended Mar 31, 2026 | $317.00K | −$2.40M | −$0.02 |
| Q2 FY2026ended Sep 30, 2025 | $191.00K | −$1.82M | −$0.02 |
| Q1 FY2026ended Jun 30, 2025 | $328.00K | −$1.60M | −$0.02 |
| Q4 FY2025ended Mar 31, 2025 | $330.00K | −$1.20M | −$0.02 |
| Q3 FY2025ended Dec 31, 2024 | $257.00K | −$1.83M | −$0.02 |
| Q2 FY2025ended Sep 30, 2024 | $412.00K | −$1.72M | −$0.02 |
| Q1 FY2025ended Jun 30, 2024 | $272.00K | −$2.38M | −$0.03 |
| Q4 FY2024ended Mar 31, 2024 | $295.00K | −$2.89M | — |
Company profile
- Name
- IGC Pharma, Inc.
- Ticker
- IGC
- Exchange
- AMEX
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 10224 Falls Road, Potomac, MD 20854
- Incorporated in
- MD
- Fiscal year ends
- December
- SEC CIK
- 0001326205
Recent SEC filings
- Aug 14, 2026
- Jul 14, 2026
- Jul 6, 2026
- Jun 8, 2026
- May 15, 2026
- Apr 20, 2026
- Mar 30, 2026
- Mar 12, 2026
Frequently asked questions
What is IGC Pharma's stock price?
IGC Pharma (IGC) closed at $834.35 on Oct 9, 2026, down 1.44% from the previous close of $846.54.
What is IGC Pharma's market cap?
IGC Pharma's market cap is $82.43B, based on a share price of $834.35 and 98.8M shares outstanding as of Mar 31, 2026.
How much revenue does IGC Pharma make?
IGC Pharma reported revenue of $1.27M for fiscal 2025, down 5.50% from fiscal 2024.
Sources and methodology
Fundamentals come from IGC Pharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures